KNSAHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc hold a median 12-month price target of $99 — +27.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 98 of 100 as at 6 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Kiniksa Pharmaceuticals International Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (98): The shares have been drifting up relative to others.
Issuance (51): The company has been issuing shares or taking on financing, diluting existing holders.
Size (20): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KNSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +27.8% from it.
Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 30 July 2026 | Goldman Sachs | Maintains | Buy | $75 → $90 |
| 29 July 2026 | Canaccord Genuity | Maintains | Buy | $64 → $98 |
| 29 July 2026 | Citigroup | Maintains | Buy | $60 → $100 |
| 29 July 2026 | JP Morgan | Maintains | Overweight | $72 → $107 |
| 29 July 2026 | Wedbush | Maintains | Outperform | $72 → $99 |
| 23 July 2026 | Goldman Sachs | Maintains | Buy | $60 → $75 |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | — |
| 13 July 2026 | Wells Fargo | Maintains | Overweight | $57 → $74 |
| 29 June 2026 | Wedbush | Maintains | Outperform | — |
| 29 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 29 Apr 2026 | Citigroup | Maintains | Buy | — |
| 29 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 29 Apr 2026 | Wells Fargo | Maintains | Overweight | — |
| 28 Apr 2026 | Jefferies | Maintains | Buy | — |
| 16 Apr 2026 | Wedbush | Maintains | Outperform | — |
| 25 Feb 2026 | Wedbush | Maintains | Outperform | — |
| 25 Feb 2026 | Wells Fargo | Maintains | Overweight | — |
| 19 Feb 2026 | Canaccord Genuity | Initiates | Buy | — |
| 13 Jan 2026 | Wedbush | Maintains | Outperform | — |
| 29 Oct 2025 | Goldman Sachs | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KNSA appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 6 Oct 2026, Kiniksa Pharmaceuticals International Plc returned +101.3% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 18% of US stocks
Cheaper than 10% of US stocks
Cheaper than 5% of US stocks
Higher than 88% of US stocks
Higher than 72% of US stocks
Higher than 67% of US stocks
Higher than 66% of US stocks
Higher than 69% of US stocks
Higher than 72% of US stocks
Higher than 88% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Kiniksa Pharmaceuticals International Plc has a market value of $5.9B and an enterprise value of $5.4B.
Revenue in the twelve months to 30 June 2026: $840.8M. The latest quarter grew 55.4% year on year.
Net income over the same four quarters: $80.7M, a 9.6% net margin.
Diluted earnings per share, trailing twelve months: $0.97.
Free cash flow in the twelve months to 30 June 2026: $182.8M.
Kiniksa Pharmaceuticals International Plc spent $11.1M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 77.1×; forward P/E: 47.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Kiniksa Pharmaceuticals International Plc employs 366 people — $2.3M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kiniksa Pharmaceuticals International Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kiniksa Pharmaceuticals' stock has rallied 41% over three months, driven by surging sales of Arcalyst and advancing pipeline developments, according to Zacks Investment Research.
Why it matters — The stock's strong performance reflects growing commercial strength in Arcalyst and pipeline progress, signaling improved fundamentals that KNSA watchers would monitor closely.
Kiniksa Pharmaceuticals announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on September 9, 2026 at 8:45 a.m. Eastern Time. The announcement was made in a press release on September 4, 2026.
Why it matters — This conference appearance offers Kiniksa's management an opportunity to discuss its business and strategy with investors and analysts in a widely attended industry forum.
An Investors Business Daily article highlights three biotech stocks that gained after their recent earnings reports and have outperformed 97% of stocks over the past 12 months.
Why it matters — This piece draws attention to biotech stocks that have delivered strong chart performance after earnings, providing relevant context for KNSA watchers tracking share-price strength in the sector.
Kiniksa Pharmaceuticals said its marketed recurrent pericarditis treatment ARCALYST continues to grow in commercial performance, and the company has started a pivotal Phase 3 study of its follow-on candidate KPL-387.
Why it matters — For KNSA watchers, ARCALYST's sustained growth supports the commercial franchise while the advancement of KPL-387 into Phase 3 signals progress in the pipeline beyond the current product.
Kiniksa Pharmaceuticals announced that its management will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:00 a.m. Eastern Time.
Why it matters — A KNSA watcher would care because the company is scheduled to speak at an investor conference, offering an opportunity for management to provide commentary to the investment community.
The 8 Wall Street analysts covering Kiniksa Pharmaceuticals International Plc have a median 12-month price target of $99, with estimates ranging from $87 to $108. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Kiniksa Pharmaceuticals International Plc, 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Kiniksa Pharmaceuticals International Plc ranks 98 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +27.8% from the last close, and Ticker Nerd's factor model ranks Kiniksa Pharmaceuticals International Plc 98 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kiniksa Pharmaceuticals International Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KNSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $87 to $108 over the next 12 months.
Kiniksa Pharmaceuticals International Plc returned +101.3% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation.
The most recent item we track (Zacks Investment Research, 17 Sept 2026): "Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why". Kiniksa Pharmaceuticals' stock has rallied 41% over three months, driven by surging sales of Arcalyst and advancing pipeline developments, according to Zacks Investment Research.
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares represents an equity interest in Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company focused on discovering, developing, and commercializing therapies for immune-mediated and inflammatory diseases. The company’s current portfolio centers on products and candidates such as ARCALYST, a marketed interleukin-1 trap used in recurrent pericarditis and related inflammatory conditions, alongside additional clinical-stage programs in immunology and inflammation. Kiniksa serves patients and healthcare providers in the United States, the United Kingdom, and other international markets, with emphasis on specialized treatments for cardiovascular and autoimmune disorders. The company’s role in the healthcare sector is defined by its concentration on targeted biologic medicines that address serious conditions with limited treatment options. Headquartered in London, Kiniksa Pharmaceuticals International, plc operates as a commercial-stage biopharmaceutical business within the global specialty drug market.
CEO Mr. Sanjiv K. Patel · 366 employees · United Kingdom · https://www.kiniksa.com
